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omen Are Like Men
. . Sometimes*
avid P. Faxon, MD
oston, Massachusetts
he impact of sex on the pathophysiology, clinical mani-
estations, and treatment of cardiovascular disease has been
topic of considerable investigation (1). The issue is an
mportant one because more than 41.3 million women are
iving with cardiovascular disease. Although progress has
een made in reducing the morbidity and mortality of heart
isease in both women and men, since 1980 the decrease in
ortality has been less for women, and disturbingly, mor-
ality has increased in women younger than 55 years of age
2). Overall cardiovascular disease remains the primary
ause of death in women.
See page 1935
Studies have shown that women with coronary artery
isease differ from men with the disease in many regards.
omen present more than 10 years older with symptomatic
oronary disease and have more risk factors at the time of
resentation, including hypertension, hyperlipidemia, and
igarette smoking. The protective effects of sex hormones
efore menopause have been thought to help explain this
bservation (3). Women also have a higher incidence of
ngina with nonobstructive coronary disease. The present-
ng symptoms of angina are less likely to be chest pain and
ore likely to be shortness of breath than in their male
ounterparts (4). They more frequently have symptoms of
eart failure with normal left ventricular function. The
utcomes of women with acute coronary syndromes (ACS),
ncluding ST-segment elevation myocardial infarction (MI)
nd revascularization with percutaneous coronary interven-
ion (PCI), have been reported to be worse than in men
5–7). In part this can be explained by the older age and
reater number of risk factors in women, but it is not
ntirely accounted for by these factors. On a positive note,
he outcomes with PCI have improved recently (6). Others
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Division of Cardiology, Brigham andm
omen’s Hospital, Boston, Massachusetts. Dr. Faxon is on the advisory boards of
ohnson & Johnson and Boston Scientific.1) have cited disparities in the delivery of care attributable
o either sex bias or lack of access to care as another
xplanation for the poorer outcome.
The mechanism for these differences in presentation,
xpression of the disease, and outcome is unclear, but
iologic differences are likely to contribute. It is known that
he blood vessels in women are smaller, stiffer, more
nflamed, and more prone to bleeding (8). Thrombosis is
entral to the pathophysiology of cardiovascular disease,
articularly MI and stroke, and is the basis for the
uideline-recommended use of antithrombotic therapy in
omen at high risk of atherothrombotic events (9). Evi-
ence from both animal studies and human studies has
hown sex differences in the development of thrombosis and
he response to antithrombotic therapy (10,11). Estrogen
as been shown to decrease plasma levels of fibrinogen,
ntithrombin, protein S, and plasminogen activator inhibi-
or (12). In a large meta-analysis, women had an increased
evel of fibrinogen (13). In addition, many studies have
hown an increase in platelet reactivity in women. In a study
y Becker et al. (14), platelets from women were more
eactive to 10 of 12 agonists than those from men. After
eceiving low-dose acetylsalicylic acid (ASA) for 14 days,
latelet function was inhibited in women to an equal degree
s in men, but because of the higher baseline reactivity the
bsolute degree of aggregation was greater in women than
en. Clinical studies of ASA for primary prevention have
hown a differential benefit in women as compared with
en. In a large meta-analysis by Berger et al. (15) of more
han 91,000 patients, ASA had no effect on the risk of MI
r cardiovascular death in women, but did lower the risk of
schemic stroke. In contrast, men experienced a reduction in
he risk of MI but no effect on ischemic stroke. Bleeding
as increased to an equivalent degree in both groups.
Sex differences associated with other antiplatelet drugs
ave also been shown. In a meta-analysis of glycoprotein
Ib/IIIa drugs by Boersma et al. (16), women with ACS
howed a worse outcome from glycoprotein IIb/IIIa agents,
hereas men showed a significant reduction in death and
I at 30 days. When patients with elevated troponin levels
ere separately evaluated, no sex differences were seen.
ore recent studies have not shown any sex differences in
utcome, possibly because of the use of concomitant clopi-
ogrel. Another potential cause for the differences in out-
omes with antithrombotic therapy in women is that they
re commonly given excess doses that result in increased
ajor bleeding and a poorer outcome. This is particularly
rue for the glycoprotein IIb/IIIa agents (17). Excessive
leeding has been linked to a poorer long-term outcome and
ncreased mortality (18).
It would therefore not be unexpected that women might
ave a less favorable response to clopidogrel as well. Studies
ave shown sex differences in CYP enzymes that are needed
o convert the pro-drug of clopidogrel into its active
etabolite. Cytochrome P450 genetic polymorphisms have
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November 17, 2009:1946–8 Women Are Like Men . . . Sometimeseen shown to reduce the responsiveness to clopidogrel, but
t is not known whether these are more common in women
19). Hyporesponsiveness to clopidogrel would be expected
o increase thrombotic events, particularly after PCI. In a
ecent study by Price (20), residual platelet reactivity was
ssessed by the bedside assay test VerifyNow P2Y12 (Ac-
umetrics Inc., San Diego, California) assay in patients on
ual-antiplatelet therapy undergoing PCI. The study
howed more platelet reactivity in women compared with
en (220  82 U vs. 299  77 U, p  0.041), and female
ex was an independent predictor of high platelet reactivity
odds ratio: 1.91; 95% confidence interval: 1.14 to 3.19; p
.014). This would support prior studies suggesting that
omen are more pro-thrombotic on standard dual-
ntiplatelet therapy and might need more aggressive anti-
latelet therapy than men.
In this issue of the Journal, Berger et al. (21) reported a
ex-specific collaborative meta-analysis of 79,613 patients
nrolled into 5 major trials of clopidogrel. The analysis
howed a reduction in the risk of cardiovascular events in
oth men and women. Although results from women were
ot statistically significantly different from those of men,
hey did show a greater reduction in MI with a nonsignif-
cant reduction in stroke and total death. Men seemed to
ave an equal benefit in the reduction of MI, stroke, and
otal death. Bleeding was increased in both and was non-
ignificantly greater in women. The results of this analysis
re reassuring and thus differ from the results seen with
spirin and glycoprotein IIb/IIIa agents. Because these
atients were on dual-antiplatelet therapy with ASA and
lopidogrel, the additional antiplatelet effect of clopidogrel
eemed to reduce adverse events, something not seen
reviously with ASA alone in primary prevention studies
15). Although this analysis strongly supports the use of
lopidogrel in addition to aspirin in women at high risk for
ardiovascular events, they also have not closed the book on
he issue of sex differences of clopidogrel. The results of a
eta-analysis are useful when the individual trials are not
dequately powered to look at less frequent events. That is
he case here, and the justification for this meta-analysis.
his type of analysis is often limited by significant differ-
nces among trials in study design, patient inclusion criteria,
efinitions, end points, and treatment regimens. In this
nalysis, for example, 2 trials studied patients with acute
I, 1 studied patients undergoing PCI, 1 evaluated patients
ith ACS, and 1 included patients with stable cardiovascu-
ar disease or those at risk for cardiovascular disease. The
ollow-up time varied from 30 days to 28 weeks, and the
aseline characteristics varied significantly among the study
opulations. Although sensitivity analysis was conducted
nd heterogeneity among trials was not seen, this analysis
oes not completely exclude an impact of the differences in
he studies on the results. Because the analysis did not
nclude patient-level data, examination of important sub-
roups was not possible. Overall the differences in the
ndividual cardiovascular events between men and womenre provocative and leave the door open for more investi-
ation of this question.
The conundrum is that women have increased throm-
otic potential with increased platelet activity but have an
ncreased risk of bleeding. What can be done to reduce
schemic complications while not increasing bleeding? Some
ave suggested platelet testing as a way to titrate therapy to
he effect desired (20). Although an attractive idea, the lack
f an accepted standardized test and uncertainty about the
ptimal level of platelet inhibition needed limits the clinical
tility (22). Another approach is to use more potent thienopy-
idines that do not need conversion in the liver, such as
rasugrel. The TRITON–TIMI 38 (Trial to Assess Improve-
ent in Therapeutic Outcomes by Optimizing Platelet Inhi-
ition with Prasugrel–Thrombolysis In Myocardial Infarction
8) study showed a significant reduction in ischemic events,
articularly stent thrombosis, but was associated with an
ncreased risk of bleeding in those treated with prasugrel as
ompared with clopidogrel (23). A number of newer, more
otent antiplatelet drugs are also in development. Others
ave suggested that an increased antiplatelet effect can be
btained by the addition of cilostazol to ASA and clopi-
ogrel (24). Cilostazol is an antiplatelet agent that increases
ntracellular cyclic adenosine monophosphate via selective
hosphodiesterase 3 inhibition. Registry studies and ran-
omized trials have suggested benefit in high-risk patients
ndergoing PCI (24–26). Of note is that in 1 of the
andomized trials, women had a substantial benefit, whereas
en did not (25).
The cumulative evidence continues to show that women
ith coronary artery disease differ from men in many
mportant ways, including the response to antiplatelet ther-
py. The good news is that clopidogrel is an exception. It is
lso critically important that future studies are designed to
dequately address the responses to therapy in women
ecause outcomes cannot be predicted by mostly male-
ominated trials. Only then can treatment be optimized for
he growing population of women with cardiovascular
isease.
eprint requests and correspondence: Dr. David P. Faxon,
righam and Women’s Hospital, 1620 Tremont Street, OBC-3-
2P, Boston, Massachusetts 02120. E-mail: dfaxon@partners.org.
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